Leerink Partnrs Issues Optimistic Forecast for BBIO Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Research analysts at Leerink Partnrs boosted their Q1 2025 EPS estimates for BridgeBio Pharma in a research note issued to investors on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings of ($0.69) per share for the quarter, up from their prior estimate of ($0.72). The consensus estimate for BridgeBio Pharma's current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma's Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.86) EPS, Q4 2025 earnings at ($0.83) EPS, FY2025 earnings at ($3.15) EPS and FY2026 earnings at ($1.58) EPS.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million for the quarter, compared to the consensus estimate of $4.04 million.

BBIO has been the subject of several other reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $95.00 price objective on shares of BridgeBio Pharma in a research report on Friday, February 21st. JPMorgan Chase & Co. raised their price target on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the stock an "overweight" rating in a research report on Monday, March 24th. Citigroup upped their price objective on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Redburn Atlantic assumed coverage on BridgeBio Pharma in a research report on Monday, March 31st. They set a "buy" rating and a $50.00 target price on the stock. Finally, Scotiabank raised their price objective on BridgeBio Pharma from $49.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Friday, February 21st. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $53.00.

BridgeBio Pharma Trading Up 3.8 %

BBIO traded up $1.29 during midday trading on Friday, reaching $35.47. The company's stock had a trading volume of 1,554,993 shares, compared to its average volume of 2,263,949. The company has a fifty day simple moving average of $33.87 and a 200 day simple moving average of $30.22. The stock has a market cap of $6.75 billion, a P/E ratio of -12.45 and a beta of 1.08. BridgeBio Pharma has a twelve month low of $21.62 and a twelve month high of $39.47.

Insiders Place Their Bets

In other BridgeBio Pharma news, CEO Neil Kumar sold 75,000 shares of the company's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $36.87, for a total transaction of $2,765,250.00. Following the completion of the sale, the chief executive officer now owns 4,948,447 shares in the company, valued at approximately $182,449,240.89. The trade was a 1.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Brian C. Stephenson sold 4,148 shares of the firm's stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $36.16, for a total value of $149,991.68. Following the completion of the transaction, the chief financial officer now owns 102,464 shares in the company, valued at $3,705,098.24. This represents a 3.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 9,694,739 shares of company stock valued at $327,308,651 in the last 90 days. 24.66% of the stock is currently owned by insiders.

Hedge Funds Weigh In On BridgeBio Pharma

Several hedge funds have recently added to or reduced their stakes in BBIO. Steward Partners Investment Advisory LLC boosted its stake in BridgeBio Pharma by 85.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock worth $28,000 after acquiring an additional 472 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of BridgeBio Pharma by 71.0% during the first quarter. GAMMA Investing LLC now owns 920 shares of the company's stock worth $32,000 after purchasing an additional 382 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new position in shares of BridgeBio Pharma in the 4th quarter valued at $41,000. Sterling Capital Management LLC increased its position in shares of BridgeBio Pharma by 554.6% in the 4th quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock valued at $49,000 after buying an additional 1,514 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new stake in shares of BridgeBio Pharma in the 4th quarter valued at $109,000. Institutional investors and hedge funds own 99.85% of the company's stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.